$80.85
+0.64 (+0.80%)
MGEE News7 articles
Amgen Lifts 2026 Forecast as Five Growth Brands Offset $772M Slump
Amgen (AMGN) raised its 2026 guidance after Q2 revenue beat estimates, as five growth brands added $923M in sales, offsetting a $772M decline from five struggling products.
CSL Shares Slide 7.4% as HEMGENIX Scale-Up Faces Supply Constraints
CSL shares dropped 7.4% last week as HEMGENIX gene therapy progress remains limited, with supply constraints and revenue concerns weighing on the stock.
Dow Dips from Record as Nike and Amgen Weigh on Blue Chips
The Dow slipped from a record intraday high as Nike and Amgen weighed heavily, while tech stocks surged on Broadcom's Apple deal and AI momentum.
Dow Hits New Peak as Apple and Amgen Lift Blue Chips; Tech Stocks Falter
The Dow set a new record close on Thursday, propelled by Apple and Amgen, as AI and chip stocks declined. Soft labor data relieved Fed pressure.
Amgen Shares Slide on FDA Setback and Enbrel Weakness, Pressuring Dow
Amgen stock fell nearly 2% Monday, pressured by an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% quarterly drop in Enbrel sales. The decline weighed on the price-weighted Dow Jones Industrial Average.
Amgen Hits 52-Week Peak on Strong Earnings; Key Data, Dividend Date Ahead
Amgen shares surged 4.5% to a 52-week high of $384.32, fueled by robust quarterly results and a dividend declaration. Investors now await delayed U.S. jobs and inflation figures.
Amgen Reaches 52-Week Peak on Friday; Investors Eye Inflation Data and Drug Pricing
Amgen shares surged 4.5% to close at $384.32 on Friday, achieving a new 52-week high. Market participants are monitoring upcoming U.S. inflation figures and developments in drug pricing.